$NRIX Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Nurix Therapeutics, Inc..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Nurix Therapeutics, Inc.. Get notifications about new insider transactions in Nurix Therapeutics, Inc. for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 24 2021 | NRIX | Nurix Therapeutics ... | Tong Jeffrey K | Director | Option Exercise | A | 27.38 | 17,500 | 479,150 | 17,500 | |
| May 24 2021 | NRIX | Nurix Therapeutics ... | Chen Leon | Director | Option Exercise | A | 27.38 | 17,500 | 479,150 | 17,500 | |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Option Exercise | M | 1.86 | 1,200 | 2,232 | 114,466 | |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 27.00 | 1,200 | 32,400 | 805 | 2 K to 805 (-59.85 %) |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Buy | M | 1.86 | 1,200 | 2,232 | 2,005 | 805 to 2 K (+149.07 %) |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | M | 1.11 | 7,500 | 8,325 | 29,062 | |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 27.66 | 700 | 19,363 | 4,330 | 5 K to 4.3 K (-13.92 %) |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 26.87 | 2,501 | 67,213 | 5,030 | 7.5 K to 5 K (-33.21 %) |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 26.07 | 4,299 | 112,068 | 7,531 | 11.8 K to 7.5 K (-36.34 %) |
| May 11 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Buy | M | 1.11 | 7,500 | 8,325 | 11,830 | 4.3 K to 11.8 K (+173.21 %) |
| May 10 2021 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Sell | J | 0.00 | 1,085,784 | 0 | 3,422,549 | 4.5 M to 3.4 M (-24.08 %) |
| May 10 2021 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Sell | J | 0.00 | 1,085,784 | 0 | 3,422,549 | 4.5 M to 3.4 M (-24.08 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 7,752 | 0 | 48,406 | 40.7 K to 48.4 K (+19.07 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 17,829 | 0 | 139,383 | 121.6 K to 139.4 K (+14.67 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 17,829 | 0 | 134,010 | 116.2 K to 134 K (+15.35 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 49,689 | 0 | 0 | 49.7 K to 0 (-100.00 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 49,689 | 0 | 49,689 | 0 to 49.7 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 1,000,000 | 0 | 989,000 | 2 M to 989 K (-50.28 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 30,347 | 0 | 40,654 | 10.3 K to 40.7 K (+294.43 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 111,247 | 0 | 121,554 | 10.3 K to 121.6 K (+1,079.33 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 105,874 | 0 | 116,181 | 10.3 K to 116.2 K (+1,027.20 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 438,338 | 0 | 0 | 438.3 K to 0 (-100.00 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 10,307 | 0 | 10,307 | 0 to 10.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 10,307 | 0 | 10,307 | 0 to 10.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 10,307 | 0 | 10,307 | 0 to 10.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 438,338 | 0 | 438,338 | 0 to 438.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 2,000,000 | 0 | 1,394,333 | 3.4 M to 1.4 M (-58.92 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 7,752 | 0 | 48,406 | 40.7 K to 48.4 K (+19.07 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 17,829 | 0 | 139,383 | 121.6 K to 139.4 K (+14.67 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 17,829 | 0 | 134,010 | 116.2 K to 134 K (+15.35 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 49,689 | 0 | 0 | 49.7 K to 0 (-100.00 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 49,689 | 0 | 49,689 | 0 to 49.7 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 1,000,000 | 0 | 989,000 | 2 M to 989 K (-50.28 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 30,347 | 0 | 40,654 | 10.3 K to 40.7 K (+294.43 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 111,247 | 0 | 121,554 | 10.3 K to 121.6 K (+1,079.33 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 105,874 | 0 | 116,181 | 10.3 K to 116.2 K (+1,027.20 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 438,338 | 0 | 0 | 438.3 K to 0 (-100.00 %) |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 10,307 | 0 | 10,307 | 0 to 10.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 10,307 | 0 | 10,307 | 0 to 10.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 10,307 | 0 | 10,307 | 0 to 10.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | J | 0.00 | 438,338 | 0 | 438,338 | 0 to 438.3 K |
| May 07 2021 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Sell | J | 0.00 | 2,000,000 | 0 | 1,394,333 | 3.4 M to 1.4 M (-58.92 %) |
| May 04 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 7.26 | 800 | 5,808 | 72,666 | |
| May 04 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Sell | S | 35.00 | 800 | 27,996 | 13,804 | 14.6 K to 13.8 K (-5.48 %) |
| May 04 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 7.26 | 800 | 5,808 | 14,604 | 13.8 K to 14.6 K (+5.80 %) |
| Apr 29 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Option Exercise | M | 1.86 | 800 | 1,488 | 115,666 | |
| Apr 29 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 35.25 | 800 | 28,200 | 805 | 1.6 K to 805 (-49.84 %) |
| Apr 29 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Buy | M | 1.86 | 800 | 1,488 | 1,605 | 805 to 1.6 K (+99.38 %) |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Option Exercise | M | 1.86 | 1,200 | 2,232 | 116,466 | |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 27.20 | 1,200 | 32,640 | 805 | 2 K to 805 (-59.85 %) |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Buy | M | 1.86 | 1,200 | 2,232 | 2,005 | 805 to 2 K (+149.07 %) |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | M | 1.11 | 5,104 | 5,665 | 36,562 | |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | M | 0.84 | 2,396 | 2,013 | 0 | |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 28.65 | 545 | 15,617 | 4,330 | 4.9 K to 4.3 K (-11.18 %) |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 27.67 | 2,883 | 79,770 | 4,875 | 7.8 K to 4.9 K (-37.16 %) |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 26.83 | 4,072 | 109,245 | 7,758 | 11.8 K to 7.8 K (-34.42 %) |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Buy | M | 1.11 | 5,104 | 5,665 | 11,830 | 6.7 K to 11.8 K (+75.88 %) |
| Apr 13 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Buy | M | 0.84 | 2,396 | 2,013 | 6,726 | 4.3 K to 6.7 K (+55.33 %) |
| Apr 06 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 7.26 | 400 | 2,904 | 73,466 | |
| Apr 06 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Sell | S | 35.00 | 400 | 14,000 | 13,804 | 14.2 K to 13.8 K (-2.82 %) |
| Apr 06 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 7.26 | 400 | 2,904 | 14,204 | 13.8 K to 14.2 K (+2.90 %) |
| Apr 02 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 7.26 | 400 | 2,904 | 73,866 | |
| Apr 02 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Sell | S | 31.55 | 400 | 12,620 | 13,804 | 14.2 K to 13.8 K (-2.82 %) |
| Apr 02 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 7.26 | 400 | 2,904 | 14,204 | 13.8 K to 14.2 K (+2.90 %) |
| Mar 25 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | M | 0.84 | 4,330 | 3,637 | 2,396 | |
| Mar 25 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Buy | M | 0.84 | 4,330 | 3,637 | 4,330 | 0 to 4.3 K |
| Mar 16 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 7.26 | 800 | 5,808 | 74,266 | |
| Mar 16 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Sell | S | 45.00 | 800 | 36,000 | 13,804 | 14.6 K to 13.8 K (-5.48 %) |
| Mar 16 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 7.26 | 800 | 5,808 | 14,604 | 13.8 K to 14.6 K (+5.80 %) |
| Mar 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Option Exercise | M | 1.86 | 2,000 | 3,720 | 117,666 | |
| Mar 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 44.11 | 395 | 17,425 | 805 | 1.2 K to 805 (-32.92 %) |
| Mar 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 42.67 | 405 | 17,280 | 1,200 | 1.6 K to 1.2 K (-25.23 %) |
| Mar 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 41.13 | 300 | 12,339 | 1,605 | 1.9 K to 1.6 K (-15.75 %) |
| Mar 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 39.44 | 900 | 35,496 | 1,905 | 2.8 K to 1.9 K (-32.09 %) |
| Mar 11 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Buy | M | 1.86 | 2,000 | 3,720 | 2,805 | 805 to 2.8 K (+248.45 %) |
| Mar 02 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 7.26 | 800 | 5,808 | 75,066 | |
| Mar 02 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Sell | S | 35.95 | 800 | 28,760 | 13,804 | 14.6 K to 13.8 K (-5.48 %) |
| Mar 02 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 7.26 | 800 | 5,808 | 14,604 | 13.8 K to 14.6 K (+5.80 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Option Exercise | M | 0.84 | 13,583 | 11,410 | 69,750 | |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Sell | S | 38.05 | 400 | 15,219 | 0 | 400 to 0 (-100.00 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Sell | S | 36.91 | 666 | 24,581 | 400 | 1.1 K to 400 (-62.48 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Sell | S | 36.00 | 5,725 | 206,109 | 1,066 | 6.8 K to 1.1 K (-84.30 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Sell | S | 35.10 | 3,652 | 128,201 | 6,791 | 10.4 K to 6.8 K (-34.97 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Sell | S | 34.24 | 3,140 | 107,511 | 10,443 | 13.6 K to 10.4 K (-23.12 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Buy | M | 0.84 | 13,583 | 11,410 | 13,583 | 0 to 13.6 K |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Option Exercise | M | 1.86 | 2,000 | 3,720 | 119,666 | |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 37.03 | 500 | 18,516 | 0 | 500 to 0 (-100.00 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 35.86 | 1,100 | 39,444 | 500 | 1.6 K to 500 (-68.75 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Sell | S | 34.48 | 400 | 13,790 | 1,600 | 2 K to 1.6 K (-20.00 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Buy | M | 1.86 | 2,000 | 3,720 | 2,000 | 0 to 2 K |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 7.26 | 800 | 5,808 | 75,866 | |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Sell | S | 37.67 | 200 | 7,534 | 12,000 | 12.2 K to 12 K (-1.64 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Sell | S | 35.81 | 600 | 21,484 | 12,200 | 12.8 K to 12.2 K (-4.69 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 7.26 | 800 | 5,808 | 12,800 | 12 K to 12.8 K (+6.67 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | M | 9.57 | 2,096 | 20,059 | 14,678 | |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | M | 7.26 | 3,797 | 27,566 | 72,869 | |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | M | 0.84 | 9,107 | 7,650 | 14,226 | |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 37.88 | 400 | 15,150 | 0 | 400 to 0 (-100.00 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 36.92 | 1,000 | 36,924 | 400 | 1.4 K to 400 (-71.43 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 35.99 | 6,400 | 230,328 | 1,400 | 7.8 K to 1.4 K (-82.05 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 35.02 | 4,553 | 159,454 | 7,800 | 12.4 K to 7.8 K (-36.86 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Sell | S | 34.19 | 2,647 | 90,496 | 12,353 | 15 K to 12.4 K (-17.65 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Buy | M | 9.57 | 2,096 | 20,059 | 15,000 | 12.9 K to 15 K (+16.24 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Buy | M | 7.26 | 3,797 | 27,566 | 12,904 | 9.1 K to 12.9 K (+41.69 %) |
| Feb 22 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Buy | M | 0.84 | 9,107 | 7,650 | 9,107 | 0 to 9.1 K |
| Feb 12 2021 | NRIX | Nurix Therapeutics ... | van Houte Hans | Chief Financial Off ... | Option Exercise | A | 38.97 | 40,000 | 1,558,800 | 40,000 | |
| Feb 12 2021 | NRIX | Nurix Therapeutics ... | SANDS ARTHUR T | President, CEO | Option Exercise | A | 38.97 | 150,000 | 5,845,500 | 150,000 | |
| Feb 12 2021 | NRIX | Nurix Therapeutics ... | Ring Christine | General Counsel | Option Exercise | A | 38.97 | 40,000 | 1,558,800 | 40,000 | |
| Feb 12 2021 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | A | 38.97 | 60,000 | 2,338,200 | 60,000 | |
| Feb 12 2021 | NRIX | Nurix Therapeutics ... | Beaurang Pierre | Chief Business Offi ... | Option Exercise | A | 38.97 | 40,000 | 1,558,800 | 40,000 | |
| Feb 08 2021 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Sell | J | 0.00 | 914,216 | 0 | 4,508,333 | 5.4 M to 4.5 M (-16.86 %) |
| Dec 01 2020 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 0.84 | 12,000 | 10,080 | 31,333 | |
| Dec 01 2020 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 0.84 | 12,000 | 10,080 | 12,000 | 0 to 12 K |
| Dec 01 2020 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Option Exercise | M | 0.84 | 12,000 | 10,080 | 31,333 | |
| Dec 01 2020 | NRIX | Nurix Therapeutics ... | Hansen Gwenn | Chief Scientific Of ... | Buy | M | 0.84 | 12,000 | 10,080 | 12,000 | 0 to 12 K |
| Oct 23 2020 | NRIX | Nurix Therapeutics ... | SANDS ARTHUR T | President, CEO | Option Exercise | A | 26.91 | 804,170 | 21,640,215 | 804,170 | |
| Jul 30 2020 | NRIX | Nurix Therapeutics ... | Wellington Biomedical Innovati ... | 10% Owner | Option Exercise | C | 0.00 | 784,313 | 0 | 0 | |
| Jul 30 2020 | NRIX | Nurix Therapeutics ... | Wellington Biomedical Innovati ... | 10% Owner | Buy | C | 0.00 | 784,313 | 0 | 784,313 | 0 to 784.3 K |
| Jul 30 2020 | NRIX | Nurix Therapeutics ... | Redmile Group, LLC | 10% Owner | Option Exercise | C | 0.00 | 1,176,470 | 0 | 0 | |
| Jul 30 2020 | NRIX | Nurix Therapeutics ... | Redmile Group, LLC | 10% Owner | Buy | C | 0.00 | 1,176,470 | 0 | 1,176,470 | 0 to 1.2 M |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 39,216 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 4,508,333 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Option Exercise | C | 0.00 | 875,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Buy | C | 0.00 | 39,216 | 0 | 5,422,549 | 5.4 M to 5.4 M (+0.73 %) |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Buy | C | 0.00 | 4,508,333 | 0 | 5,383,333 | 875 K to 5.4 M (+515.24 %) |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | Third Rock Ventures III, L.P. | 10% Owner | Buy | C | 0.00 | 875,000 | 0 | 875,000 | 0 to 875 K |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 686,274 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 686,274 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 686,274 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 686,274 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 1,989,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 1,989,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 1,836,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 1,836,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 875,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 875,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 600,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Option Exercise | C | 0.00 | 600,000 | 0 | 0 | |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 686,274 | 0 | 686,274 | 0 to 686.3 K |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 686,274 | 0 | 686,274 | 0 to 686.3 K |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 686,274 | 0 | 686,274 | 0 to 686.3 K |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 686,274 | 0 | 686,274 | 0 to 686.3 K |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 1,989,000 | 0 | 1,989,000 | 0 to 2 M |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 1,989,000 | 0 | 1,989,000 | 0 to 2 M |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 1,836,000 | 0 | 3,394,333 | 1.6 M to 3.4 M (+117.82 %) |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 1,836,000 | 0 | 3,394,333 | 1.6 M to 3.4 M (+117.82 %) |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 875,000 | 0 | 1,558,333 | 683.3 K to 1.6 M (+128.05 %) |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 875,000 | 0 | 1,558,333 | 683.3 K to 1.6 M (+128.05 %) |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 600,000 | 0 | 683,333 | 83.3 K to 683.3 K (+720.00 %) |
| Jul 29 2020 | NRIX | Nurix Therapeutics ... | COLUMN GROUP L P | 10% Owner | Buy | C | 0.00 | 600,000 | 0 | 683,333 | 83.3 K to 683.3 K (+720.00 %) |